For the Inventor, By the Inventor

Enter assignee name

Heidelberg, Germany

Apogenix Ag

USPTO Granted Patents = 27

CIPO Patents = 52

EPO Patents = 17

Trademarks = 6

Forward Citations = 38

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Christian Gieffers (26 out of 37 patents)

Oliver Hill (25 out of 35 patents)

Meinolf Thiemann (25 out of 38 patents)

4. Tim Schnyder (9 out of 9 patents)

5. Harald Fricke (4 out of 4 patents)

6. Jaromir Sykora (3 out of 3 patents)

7. Christian Merz (2 out of 2 patents)

8. Marcus Branschädel (2 out of 5 patents)

9. Marcus Branschaedel (2 out of 3 patents)

10. Claudia Kunz (1 out of 14 patents)

11. Michaela Fontenay (1 out of 6 patents)

12. Susan E Lappe (1 out of 4 patents)

13. Fritz G Buchanan (1 out of 1 patent)

14. Darren C Phillips (1 out of 1 patent)

15. Marcus Branschadel (0 patent)

27 patents: Sort by Forward Citations

1. 11214605 - Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells (2022-01-04),

2. 11149075 - Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins (2021-10-19),

3. 11014991 - Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody (2021-05-25),

4. 10870688 - Single-chain CD137-receptor agonist proteins (2020-12-22),

5. 10844108 - Single-chain CD27-receptor agonist proteins (2020-11-24),

6. 10793616 - Single-chain CD40-receptor agonist proteins (2020-10-06),

7. 10683338 - Single-chain TL1A receptor agonist proteins (2020-06-16),

8. 10683332 - Single-chain light receptor agonist proteins (2020-06-16),

9. 10640543 - CD27 ligand (CD27L) single-chain fusion polypeptides (2020-05-05),

10. 10533043 - Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins (2020-01-14),

11. 10519217 - CD27L collectin fusion proteins and encoding nucleic acids (2019-12-31),

12. 10519208 - CD40L single-chain fusion polypeptides and encoding nucleic acids (2019-12-31),

13. 10428154 - Monoclonal anti-CD95L antibody (2019-10-01),

14. 10370441 - Nucleic acids encoding artificial signal peptides and methods of production thereof (2019-08-06),

15. 10266600 - Diagnostic anti-CD95L antibody (2019-04-23),

Apogenix AG is a German biopharmaceutical company specializing in targeted immunotherapies for the treatment of cancer and other life-threatening diseases. With a focus on developing novel antibody-based drugs, Apogenix aims to harness the power of the immune system to fight against various diseases. Their innovative approach includes the development of CD40 ligand (CD40L) inhibitors and apoptosis-inducing proteins (APs) for the treatment of solid tumors, as well as the development of immunomodulatory antibodies for the treatment of inflammatory diseases. Apogenix AG is committed to providing patients with effective and safe treatments that can significantly improve their quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

27 Patents

#12 in Heidelberg

#1,760 in Germany

#23,254 in the World

Heidelberg, Germany

Apogenix Ag

Forward Citations = 38

37 inventors:

Christian Gieffers (26 out of 37 patents)

Oliver Hill (25 out of 35 patents)

Meinolf Thiemann (25 out of 38 patents)

4. Tim Schnyder (9 out of 9 patents)

5. Harald Fricke (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…